Posts Tagged ‘a-wide-range’

Hair Restoration Treatment Uses Novel Stem Cell Therapy …

Stem Cell Medicine | Posted by admin
Oct 12 2015

DALLAS UPTOWN and PLANO, Texas, Oct. 10, 2015 /PRNewswire/ — For men and women who are just beginning to deal with thinning hair, there is a new way to possibly reverse thinning which does not involve tedious follicle-by-follicle transplantation: platelet-rich plasma (P.R.P.), drawn from one’s own blood, optimized, and then re-injected into the scalp. P.R.P. contains a large number of adult stem cells, which are known to stimulate cell growth.

A patients’ own platelet-rich blood plasma has been utilized in various cosmetic procedures developed over the past several years to encourage the formation of fresh collagen in the face and hands; now, platelet-rich plasma is being micro-injected into the scalp to stimulate renewed, thicker hair growth.

Medical Director Dr. Jeffrey Adelglass and Director of Dermatology Dr. Elizabeth Houshmand of SKINTASTIC Cosmetic Surgery and Laser Skin Care Centers recently added Platelet Rich Plasma Hair Restoration to their already expansive list of face, body, skincare, and wellness services. While P.R.P. hair growth stimulation can be considered somewhat novel, the cellular science behind it has already expanded into a wide range of medical modalities.

Dr. Adelglass explains, “Working with platelet rich plasma, the overall success is very ‘donor-dependent.’ We carefully screen our prospective PRP patients for medications and other substances known to inhibit the PRP growth factor’s ability to ‘take,’ such as tobacco. Also, P.R.P. therapy is not effective for treating hair roots that are no longer living.”

Consultations at SKINTASTIC for P.R.P. Hair Restoration are recommended with Dr. Houshmand, a double board certified dermatologist, to assess whether or not one is a qualified candidate for this procedure. Dr. Houshmand is also an instructor who teaches the technique to other physicians. She briefly explains the procedure: “P.R.P. Hair Growth is an outpatient procedure at SKINTASTIC. Our technician draws a single vial of blood, and we spin it up in the centrifuge to separate the plasma, which is then prepared and immediately micro-injected into the treatment areas. Patients may see their first noticeable hair growth several weeks after their treatment.”

Those interested in learning more about P.R.P. Hair Growth Therapy should make an appointment at SKINTASTIC Cosmetic Surgery and Laser Skin Centers in Dallas Uptown or Plano, Texas by calling (972) 620-3223, or at skintastic.com.

Media: Contact Jeffrey Adelglass, M.D., F.A.C.S. at (214) 392-8830, or jeffadel@gmail.comand Elizabeth Houshmand MD FAAD, FABIM at (484) 838-0487 or elizabeth2713@hotmail.com.

Doctors Adelglass or Houshmand may be available for interview on advances in cosmetic surgery and new beauty technologies, or to speak to groups regarding this or other related topics.

SOURCE SKINTASTIC Cosmetic Surgery and Laser Skin Care Centers

RELATED LINKS http://skintastic.com

More:
Hair Restoration Treatment Uses Novel Stem Cell Therapy …

Stem Cell Therapy Clinics In Canada | Stem Cell Medical …

Stem Cell Clinics | Posted by admin
Aug 02 2015

Unique Cell Treatment Clinic is glad to help you. Unique Cell Treatment Clinic since 1994 has successfully treated a wide range of diseases with preparations based on

Stem Cell Research Pros and Cons Biotech/Biomedical About.com Scientists Continue Stem Cell Research While Courts Debate Ban Spencer Platt/Getty The CIHR (Canadian Institute of Health Sciences) drafted a list of

underlie that stem cells cant be offered as therapy. They can only be used in clinical trials after approval from the Drug Controller General of India. In India, many unauthorised clinics are offering it as a cure. Whichever private clinic

Stem Cell Research And Diabetes Treatment Pros & Cons of Embryonic Stem Cell Research Liberal Politics Most scientists believe that embryonic stem cells hold

Both Brodie and Howe received stem cell treatments at a clinic in nearby Tijuana, Mexico. Cherry Starr said she agreed not to talk about the companies and location involved in her husbands treatment until a later

Jun 30, 2014 Progress is being made in the area of stem cell treatment of different types of Dr. Freedman presented data from the Canadian MS Bone and

Jul 10, 2010 The International Society for Stem Cell Research (ISSCR) offers tools to assist patients as they consider a clinic or treatment for stem cell

Brodie and Howe received stem cell treatments at a clinic in nearby Tijuana, Mexico. Cherry Starr told USA Today that she agreed not to discuss the companies and location involved in her husbands medical care, but

Duncan Stewart of The Ottawa Hospital and the University of Ottawa has published promising results of the first clinical trial in the world of a genetically-enhanced stem cell therapy for pulmonary arterial hypertension.

Jan 1, 2014 To learn more about stem cell therapy and COPD, read this interview There is so much going on now and most stem cell doctors do believe

Continue reading here:
Stem Cell Therapy Clinics In Canada | Stem Cell Medical …

The Power of Stem Cells | California’s Stem Cell Agency

Stell Cell Research | Posted by admin
Jul 18 2015

En Espaol

Stem cells have the potential to treat a wide range of diseases. Here, discover why these cells are such a powerful tool for treating diseaseand what hurdles experts face before new therapies reach patients.

How can stem cells treat disease? What diseases could be treated by stem cell research? How can I learn more about CIRM-funded research in a particular disease? What cell therapies are available right now? When will therapies based on embryonic stem cells become available? What about the therapies that are available overseas? Why does it take so long to create new therapies? How do scientists get stem cells to specialize into different cell types? How do scientists test stem cell therapies? Can’t stem cell therapies increase the chances of a tumor? Is there a risk of immune rejection with stem cells? How do scientists grow stem cells in the right conditions?

When most people think about about stem cells treating disease they think of a stem cell transplant.

In a stem cell transplant, embryonic stem cells are first specialized into the necessary adult cell type. Then, those mature cells replace tissue that is damaged by disease or injury. This type of treatment could be used to:

But embryonic stem cell-based therapies can do much more.

Any of these would have a significant impact on human health without transplanting a single cell.

In theory, theres no limit to the types of diseases that could be treated with stem cell research. Given that researchers may be able to study all cell types via embryonic stem cells, they have the potential to make breakthroughs in any disease.

CIRM has created disease pages for many of the major diseases being targeted by stem cell scientists. You can find those disease pages here.

You can also sort our complete list of CIRM awards to see what we’ve funded in different disease areas.

The rest is here:
The Power of Stem Cells | California’s Stem Cell Agency

Postdoctoral position in Stem Cell Development and Cancers

Stem Cell Medical Center | Posted by admin
Jul 02 2015

Postdoctoral positions are immediately available in the laboratory of Dr. Jian Xu, in the Childrens Research Institute of UTSouthwestern Medical Center to study the epigenetic regulation of normal and malignant blood stem cell development. Our laboratory focuses on the intersection of transcriptional control with stem cell biology, hematopoiesis and cancer. We employ epigenetics, functional genomics, genome editing, and mouse genetics to define epigenetic and genetic programs controlling blood stem cell development, and how these processes go awry in cancer progression. By comparing the ontogeny of gene networks in normal and neoplastic hematopoiesis, we aim to understand how non-coding regulatory genome, lineage-specifying regulators, and epigenetic modulators cooperate to control developmental potency, and how aberrations lead to cancer development. The laboratory is equipped with cutting-edge genomics and bioinformatics platforms, and has access to numerous shared facilities including metabolomics, imaging, and flow cytometry. Our laboratory brings together enthusiastic scientists with diverse backgrounds, and provides a wide range of perspectives in a multi-disciplinary and collaborative team setting. Please refer to our representative publications for details about the ongoing research: Nature 460:1093-1097; Science 334:993-996; Cell, 151:929-931; Dev Cell, 23:796-811; Mol Cell, 57:304-316; Cell Stem Cell 14:68-80; NEJM, 365:807-814; G&D 23:2824-2838.

The successful candidate must hold a Ph.D. and/or M.D. degree with a strong background in mouse genetics, blood cell development and disorders, molecular biology, or a related field. The ideal candidate will exhibit independence, flexibility and creativity with a record of scientific productivity. Previous experience in generating and analyzing mouse models, epigenetics, genomic engineering, and/or hematology-oncology is strongly preferred.

To apply please submit CV, a short summary of research interest and experience, and a list of three references to:

Jian Xu, PhD

Assistant Professor, Childrens Research Institute

CPRIT Scholar in Cancer Research

American Society of Hematology Scholar

UT Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-8502

Continue reading here:
Postdoctoral position in Stem Cell Development and Cancers

One type of lung cell can regenerate as another type of lung cell, study finds

Stem Cell Medicine | Posted by admin
Apr 14 2015

April 13, 2015

Adult lung cells regenerating: Type 1 cells are green. Type 2 cells are red. New Type 2 derived from Type 1 cells are yellow. Nuclei are blue. (Credit: Jon Epstein, MD & Rajan Jain, MD, Perelman School of Medicine at the University of Pennsylvania, and Christina Barkauskas & Brigid Hogan, Duke University)

Brett Smith for redOrbit.com @ParkstBrett

When we think of tissue regeneration, we typically think of stem cells and their capacity to develop into a wide range of different cell types.

However, a team of scientists from Duke University and the University of Pennsylvania have shown that certain cells in the lungs are able to give rise to other lung cell types, according to a new study in the journal Nature Communications.

Its as if the lung cells can regenerate from one another as needed to repair missing tissue, suggesting that there is much more flexibility in the system than we have previously appreciated, said study author Dr. Jon Epstein, chair of the department of Cell and Developmental Biology at Penn. These arent classic stem cells that we see regenerating the lung. They are mature lung cells that awaken in response to injury.

We want to learn how the lung regenerates so that we can stimulate the process in situations where it is insufficient, such as in patients with COPD (chronic obstructive pulmonary disease), he added.

A mind of its own

There are two types of cells in the air sacs of the lung known as alveoli. Long, slender Type 1 cells are where inhaled gases are exchanged. Type 2 cells release surfactant, a soapy compound that assists in keeping airways open. Sometimes, premature babies need to be given surfactant to assist them with breathing.

In the study, the team used mouse models to find that both of these kinds of cells are derived from a standard precursor stem cell in the embryo. Next, the researchers used other mouse models involving part of the lung that was removed for cell cultures to examine the plasticity of cell types throughout lung regeneration. The team saw that Type 1 cells can give rise to Type 2 cells, and vice-versa.

Originally posted here:
One type of lung cell can regenerate as another type of lung cell, study finds

Cleveland Clinic Researchers First to Demonstrate Significant Blocking of Opioid Tolerance With Mesenchymal Stem Cell …

Cell Medicine | Posted by admin
Mar 25 2015

Contact Information

Available for logged-in reporters only

Newswise March 24, 2015, NATIONAL HARBOR, Md. – Mesenchymal stem cell (MSC) transplantation reduced opioid tolerance and opioid-induced hyperalgesia caused by daily morphine injections in rats, according to new research. The results could herald stem cell transplantation as an innovative, safe, efficacious and cost-effective therapy to treat pain and opioid tolerance, said researchers, who presented results in a Plenary Research Highlight session at the 31st Annual Meeting of the American Academy of Pain Medicine.

Not only was opioid tolerance prevented when the rats were transplanted with MSC before repeated morphine injections, but tolerance was reversed when the rats were treated after opioid tolerance had developed, results demonstrated.

MSCs have a remarkable anti-inflammatory effect and a powerful anti-tolerance effect, said the studys principal investigator, Jianguo Cheng, M.D., Ph.D., who led the research team from the Cleveland Clinic, in Ohio. Although clinical trials are still three to five years away, he said, eventually, The results may apply to millions of patients with a wide range of pain states, including cancer pain and other intractable chronic pain that requires long-term opioid therapy.

Furthermore, Cheng characterized the procedure as practical, in light of readily available sources of stem cells, reliable stem cell technology, the simplicity of transplantation procedures and the fact that clinical trials are already underway involving autoimmune and other diseases.

The Institute of Medicine report on pain in America documented millions who suffer with chronic pain (Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press [US]; 2011). Opioid therapy is a cornerstone component of pain management for many people with severe, ongoing pain; however, side effects such as tolerance and the risks posed by abuse, addiction and drug overdose limit its utility. Tolerance, a physiologic process in which the patients body adjusts to a dose and no longer achieves pain relief, is a common limitation with opioid therapy. The higher doses that result can limit effectiveness and compromise safety.

Glial cells are of growing interest in pain research and have been implicated in the development of tolerance. Glial cell activity also produces pain through the release of products that excite the nervous system, playing an important role in the spinal cord during nerve injury. Furthermore, the opioids used to treat pain, also can induce glial activity, causing pain relief to drop and unwanted opioid effects, including tolerance, dependence, reward and decreased breathing, to grow. A focus of research, then, is to separate the desired effect of pain relief from the unwanted opioid effects (Watkins et al, Trends in Pharmacological Sciences 2009;30(11): 581-91).

Interest in transplant of stem cells is another maturing research avenue (Hsu et al, Cell Transplant 2007;16(2):133-50). MSCs can differentiate into a variety of cell types and have been investigated for potential repair of damaged neural cells and for calming inflammation in the immune system to promote recovery after traumatic brain injury (Zhang et al, J Neuroinflammation 2013;10(1):106).

Following this line of research, the study investigators wondered whether they could create an anti-tolerance therapy by transplanting MSCs into the intrathecal space surrounding the spinal cord. With approval by the Cleveland Clinic Institutional Animal Care and Use Committee and funding through the Department of Defenses Congressionally Directed Medical Research Programs, they compared the withdrawal thresholds of the hind paws in response to painful mechanical and thermal stimuli in two groups of rats that received daily morphine injections. The first group was treated with MSC transplantation and the control group with phosphate-buffered saline (PBS).

Read more:
Cleveland Clinic Researchers First to Demonstrate Significant Blocking of Opioid Tolerance With Mesenchymal Stem Cell …

Regenestem Network and Gilberto Hernandez Falcon, M.D. Open Stem Cell Clinic in Yucatan

Cell Medicine | Posted by admin
Jan 31 2015

MIAMI (PRWEB) January 30, 2015

Regenestem Network has announced the grand opening of a new stem cells clinic in the prestigious Hospital Clinica de Merida in Yucatan, Mexico. The new clinic will operate under the direction of Gilberto Hernandez Falcon, M.D., a member of the Global Stem Cells Advisory Board and CEO of Regenestem Mexico Sur in Villahermosa Tabasco.

The Yucatan facility is the newest in a growing number of Regenestem clinics providing comprehensive regenerative medicine services worldwide. Plans include equipping the new clinic with the latest technology from the Adilyfe line of stem cell treatment products, made available through Global Stem Cells Group affiliate Adimarket.

Expanding the Regenestem Network throughout Mexico is a great opportunity to bring cutting edge medical advancements to patients, while creating and sustaining new jobs for medical professionals in the Central America region, says Regenestem Founder and CEO Ricardo DeCubas. Were proud to be working with Dr. Hernandez Falcon in making stem cell medicine available to a growing number of patients in the region.

The new Regenestem Yucatan facility will offer the most advanced protocols and techniques available in stem cell medicine.

I am proud to continue to provide stem cell therapies to a wide range of patients here in Mexico and the Central America region, Hernandez Falcon says. Working with the Regenestem Network and Global Stem Cells Group has allowed us to help more and more patients access promising treatments for a range of medical problems.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem:

Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

View post:
Regenestem Network and Gilberto Hernandez Falcon, M.D. Open Stem Cell Clinic in Yucatan

ESI BIO A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific

Stem Cell Clinic | Posted by admin
Jan 27 2015

ALAMEDA, Calif.–(BUSINESS WIRE)–ESI BIO, the stem cell products division of BioTime, Inc., announces that its cGMP and research grade stem cell lines, reagents and cell matrix products are now available in the UK and Ireland through 2BScientific Ltd.

ESI BIOs (esibio.com) research products are used by stem cell researchers around the world and include clinical and research grade human embryonic stem cells from ES Cell International (ESI) and HyStem hyaluronan-based hydrogel extracellular matrices. ESI BIO also provides unique PureStem Embryonic Progenitors, antibodies and small molecules for stem cell differentiation and reprogramming.

Jeffrey Janus, CEO at ESI BIO commented, “We are pleased to hear that 2BScientific would like to be our distributor in the UK market and we expect that we can build a strong partnership in the future.” James Bernard, CEO of 2BScientific added, “2BScientific is excited to have signed a distribution agreement with ESI BIO to sell all of their stem cell products and services in the United Kingdom and Ireland. We are excited to offer their cell lines and supporting products for stem cell researchers.”

About ESI BIO

ESI BIO – A Division of BioTime, Inc., markets and distributes stem cell related research products provided by BioTime and its subsidiary companies. Many of these products can be provided as a research grade or clinical grade, including ES Cell Internationals human embryonic stem cell lines and HyStem hyaluronan-based hydrogels produced under conditions designed to be compliant with principles of current Good Manufacturing Practices (cGMP), making them suitable for use in clinical research and regenerative medicine. ESI BIO’s portfolio includes PureStem human embryonic progenitors, antibodies, and small molecules for stem cell differentiation and reprogramming. ESI BIO’s mission is to develop innovative research products that help translate scientific discoveries to the clinic. ESI BIO facilities are located in La Jolla and Alameda, California. Learn more at http://www.esibio.com.

About 2B Scientific

2B Scientific is a specialist distributor of immunological reagents to the UK life science market. 2B Scientific takes a novel approach to life science reagents distribution and provides a wide range of products including antibodies, PCR and flow cytometry reagents, apoptosis assays, proteins and life science consumables. Learn more at http://www.2BScientific.com.

Read more from the original source:
ESI BIO A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific

Team isolates stem cell that gives rise to bones, cartilage in mice

Stem Cell Medical Center | Posted by admin
Jan 16 2015

13 hours ago Hematopoietic precursor cells: promyelocyte in the center, two metamyelocytes next to it and band cells from a bone marrow aspirate. Credit: Bobjgalindo/Wikipedia

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

“Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn’t heal well, but that lack of cartilage predisposes the patient to arthritis down the road,” said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. “This research raises the possibility that we can create new skeletal stem cells from patients’ own tissues and use them to grow new cartilage.” Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stromathe spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

“Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells,” said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

“If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another,” said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Continued here:
Team isolates stem cell that gives rise to bones, cartilage in mice

Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

Cell Medicine | Posted by admin
Jan 16 2015

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

“Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn’t heal well, but that lack of cartilage predisposes the patient to arthritis down the road,” said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. “This research raises the possibility that we can create new skeletal stem cells from patients’ own tissues and use them to grow new cartilage.” Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stroma — the spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

“Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells,” said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

“If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another,” said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Reprogramming fat cells

The rest is here:
Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice